GNRH1 and prostate carcinoma: One of the factors is hormonal therapy, which was seen in prostate cancer patients receiving luteinizing hormone-releasing hormone (LHRH) analogs during the treatment [32] Patients receiving this additional treatment along with immunotherapy may have had an influence on the overall effect of the results, as LHRH analogs aid in the inhibition of prostate cancer growth [44].